pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Approved indications of anti-dementia drugs and choline alfoscerate

DonepezilAlzheimer’s dementia

Rivastigmine1. Mild ∼ moderate Alzheimer’s dementia2. Mild ∼ moderate Parkinson’s dementia

GalantamineMild ∼ moderate Alzheimer’s dementia

MemantineModerate ∼ moderately severe Alzheimer’s dementia

Choline alfoscerate1. Secondary symptom and metamorphosis or degenerative brain-organic psychiatric syndrome by cerebrovascular deficiency: reduced memory, derangement, disorientation by reduced willingness and spontaneity, reduced willingness and spontaneity, reduced concentration
2. Emotional and behavioral change: emotional insecurity, sensitive to stimulation, indifferent to surrounding
3. Senile pseudodepression
Korean J Clin Pharm 2019;29:1-8 https://doi.org/10.24304/kjcp.2019.29.1.1
© 2019 Korean J Clin Pharm